A PANorama of PAX genes in cancer and development

Nature Reviews Cancer

Volumn 6, Issue 1, 2006, Pages 52-62

  Robson, Ewan J D ^a   He, Shu Jie ^a   Eccles, Michael R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX4; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR PAX7; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR PAX9;

APOPTOSIS; B CELL LYMPHOMA; CANCER GENETICS; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CHROMOSOME TRANSLOCATION; CPG ISLAND; DOWN REGULATION; EMBRYO DEVELOPMENT; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; HUMAN; MELANOMA; MOLECULAR MECHANICS; MORPHOGENESIS; MULTIGENE FAMILY; MUSCLE REGENERATION; NEPHROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; EMBRYONIC DEVELOPMENT; HUMANS; NEOPLASMS; PAIRED BOX TRANSCRIPTION FACTORS;

EID: 30144439616     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1778     Document Type: Review

References (130)

1. Dahl, E., Koseki, H. & Balling, R. Pax genes and organogenesis. Bioessays 19, 755-765 (1997).
2. Seale, P. et al. Pax7 is required for the specification of myogenic satellite cells. Cell 102, 777-786 (2000).
3. Cai, Q. et al. Pax2 expression occurs in renal medullary epithelial cells in vivo and in cell culture, is osmoregulated, and promotes osmotic tolerance. Proc. Natl Acad. Sci. USA 102, 503-508 (2005).
4. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
5. Yamaoka, T. et al. Diabetes and pancreatic tumours in transgenic mice expressing Pax 6. Diabetologia 43, 332-339 (2000).
6. Muratovska, A., Zhou, C., He, S., Goodyer, P. & Eccles, M. R. Paired-box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22, 7989-7997 (2003).
7. Bernasconi, M., Remppis, A., Fredericks, W. J., Rauscher, F. J., & Schafer, B. W. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc. Natl Acad. Sci. USA 93, 13164-13169 (1996). The first report that apoptosis occurs on downregulation of Pax gene expression in cancer cells.
8. Scholl, F. A. et al. PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res. 61, 823-826 (2001).
9. He, S. J., Stevens, G., Braithwaite, A. W. & Eccles, M. R. Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol. Cancer Ther. 4, 996-1003 (2005).
10. Gnarra, J. R. & Dressler, G. R. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res. 55, 4092-4028 (1995).
11. Buttiglieri, S. et al. Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J. Biol. Chem. 279, 4136-4143 (2004).
12. Zhou, Y. H., Tan, F., Hess, K. R. & Yung, W. K. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin. Cancer Res. 9, 3369-3375 (2003).
13. Gerber, J. K. et al. Progressive loss of PAX9 expression correlates with increasing malignancy of dysplastic and cancerous epithelium of the human oesophagus. J. Pathol. 197, 293-297 (2002).
14. Zhou, Y. H. et al. PAX6 suppresses growth of human glioblastoma cells. J. Neurooncol. 71, 223-229 (2005). References 12-14 demonstrate the favourable effect that PAX6 or PAX9 expression has on cancer cell growth.
15. Eberhard, D. & Busslinger, M. The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins. Cancer Res. 59, 1716S-1724S (1999).
16. Yuan, S. S., Yeh, Y. T. & Lee, E. Y. Pax-2 interacts with RB and reverses its repression on the promoter of Rig-1, a Robo member. Biochem. Biophys. Res. Commun. 296, 1019-1025 (2002).
17. Miccadei, S., Provenzano, C., Mojzisek, M., Giorgio Natali, P. & Civitareale, D. Retinoblastoma protein acts as Pax 8 transcriptional coactivator. Oncogene 24, 6993-7001 (2005).
18. Relaix, F., Rocancourt, D., Mansouri, A. & Buckingham, M. Divergent functions of murine Pax3 and Pax7 in limb muscle development. Genes Dev. 18, 1088-1105 (2004).
19. Tremblay, P., Kessel, M. & Gruss, P. Atransgenic neuroanatomical marker identifies cranial neural crest deficiencies associated with the Pax3 mutant Splotch. Dev. Biol. 171, 317-329 (1995).
20. Tremblay, P. et al. A crucial role for Pax3 in the development of the hypaxial musculature and the long-range migration of muscle precursors. Dev. Biol. 203, 49-61 (1998).
21. Conway, S. J., Henderson, D. J., Kirby, M. L., Anderson, R. H. & Copp, A. J. Development of a lethal congenital heart defect in the splotch (Pax3) mutant mouse. Cardiovasc. Res. 36, 163-173 (1997).
22. Goulding, M., Lumsden, A. & Paquette, A. J. Regulation of Pax-3 expression in the dermomyotome and its role in muscle development. Development 120, 957-971 (1994).
23. Buckiova, D. & Syka, J. Development of the inner ear in Splotch mutant mice. Neuroreport 15, 2001-2005 (2004).
24. Tassabehji, M. et al. PAX3 gene structure and mutations: close analogies between Waardenburg syndrome and the Splotch mouse. Hum. Mol. Genet. 3, 1069-1074 (1994).
25. Borycki, A. G., Li, J., Jin, F., Emerson, C. P. & Epstein, J. A. Pax3 functions in cell survival and in pax7 regulation. Development 126, 1665-1674 (1999).
26. -/- mutant mice. Development 122, 831-838 (1996).
27. Oustanina, S., Hause, G. & Braun, T. Pax7 directs postnatal renewal and propagation of myogenic satellite cells but not their specification. EMBO J. 23, 3430-3439 (2004).
28. Olguin, H. C. & Olwin, B. B. Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev. Biol. 275, 375-388 (2004).
29. Lang, D. et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433, 884-887 (2005). This paper first introduces the concept of Pan genes.
30. Tiffin, N., Williams, R. D., Shipley, J. & Pritchard-Jones, K. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br. J. Cancer 89, 327-332 (2003).
31. Barr, F. G. et al. Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. Cancer Res. 59, 5443-5448 (1999).
32. Frascella, E., Toffolatti, L. & Rosolen, A. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet. Cytogenet. 102, 104-109 (1998).
33. Schulte, T. W., Toretsky, J. A., Ress, E., Helman, L. & Neckers, L. M. Expression of PAX3 in Ewing's sarcoma family of tumors. Biochem. Mol. Med. 60, 121-126 (1997).
34. Harris, R. G., White, E., Phillips, E. S. & Lillycrop, K. A. The expression of the developmentally regulated proto-oncogene Pax-3 is modulated by N-Myc. J. Biol. Chem. 277, 34815-34825 (2002).
35. Racz, A. et al. Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma. Int. J. Oncol. 17, 67-73 (2000).
36. Sorensen, P. H. et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 20, 2672-2679 (2002).
37. Helman, L. J. & Meltzer, P. Mechanisms of sarcoma development. Nature Rev. Cancer 3, 685-694 (2003).
38. Xia, S. J. & Barr, F. G. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene 23, 6864-6871 (2004).
39. Matsuzaki, Y. et al. Systematic identification of human melanoma antigens using serial analysis of gene expression (SAGE). J. Immunother. 28, 10-19 (2005).
40. Takeuchi, H. et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J. Clin. Oncol. 22, 2671-2680 (2004). This paper shows that PAX3 expression is a prognostic marker predicting poor outcome in patients with melanoma.
41. Margue, C. M., Bernasconi, M., Barr, F. G. & Schafer, B. W. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3-FKHR. Oncogene 19, 2921-2929 (2000).
42. Wada, H., Holland, P. W., Sato, S., Yamamoto, H. & Satoh, N. Neural tube is partially dorsalized by overexpression of HrPax-37: the ascidian homologue of Pax-3 and Pax-7. Dev. Biol. 187, 240-252 (1997).
43. Tremblay, P., Pituello, F. & Gruss, P. Inhibition of floor plate differentiation by Pax3: evidence from ectopic expression in transgenic mice. Development 122, 2555-2567 (1996). This paper presents the first evidence that ectopic Pax3 expression promotes maintenance of a progenitor cell state.
44. Relaix, F. et al. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev. 17, 2950-2965 (2003).
45. Cramer, A. et al. Activation of the c-Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3. J. Cell Biochem. 95, 805-816 (2005).
46. +/- mutant mice. Hum. Mol. Genet. 9, 1-11 (2000).
47. Torban, E., Eccles, M. R., Favor, J. & Goodyer, P. R. PAX2 suppresses apoptosis in renal collecting duct cells. Am. J. Pathol. 157, 833-842 (2000).
48. Clark, P., Dziarmaga, A., Eccles, M. & Goodyer, P. Rescue of defective branching nephrogenesis in renal-coloboma syndrome by the caspase inhibitor, Z-VAD-fmk. J. Am. Soc. Nephrol. 15, 299-305 (2004).
49. Burton, Q., Cole, L. K., Mulheisen, M., Chang, W. & Wu, D. K. The role of Pax2 in mouse inner ear development. Dev. Biol. 272, 161-175 (2004).
50. Silberstein, G. B., Dressler, G. R. & Van Horn, K. Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene 21, 1009-1016 (2002). This paper is the first to identify a possible role for PAX2 in mammary stem-cell survival and highlights potential recapitulation of developmental function in breast cancer.
51. Mansouri, A., Chowdhury, K. & Gruss, P. Follicular cells of the thyroid gland require Pax8 gene function. Nature Genet. 19, 87-90 (1998).
52. Eccles, M. R. & Schimmenti, L. A. Renal-coloboma syndrome: a multi-system developmental disorder caused by PAX2 mutations. Clin. Genet. 56, 1-9 (1999).
53. Rothenpieler, U. W. & Dressler, G. R. Pax-2 is required for mesenchyme-to-epithelium conversion during kidney development. Development 119, 711-720 (1993).
54. Torres, M., Gomez-Pardo, E., Dressier, G. R. & Gruss, P. Pax-2 controls multiple steps of urogenital development. Development 121, 4057-4065 (1995).
55. Davies, J. A. et al. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum. Mol. Genet. 13, 235-246 (2004).
56. Bouchard, M., Souabni, A., Mandler, M., Neubuser, A. & Busslinger, M. Nephric lineage specification by Pax2 and Pax8. Genes Dev. 16, 2958-2970 (2002).
57. Li, H., Liu, H., Corrales, C. E., Mutai, H. & Heller, S. Correlation of Pax-2 expression with cell proliferation in the developing chicken inner ear. J. Neurobiol. 60, 61-70 (2004).
58. Eccles, M. R. et al. Expression of the PAX2 gene in human fetal kidney and Wilms' tumor. Cell Growth Differ. 3, 279-289 (1992).
59. Dressler, G. R. et al. Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities. Nature 362, 65-67 (1993).
60. Dziarmaga, A. et al. Ureteric bud apoptosis and renal hypoplasia in transgenic PAX2-Bax fetal mice mimics the renal-coloboma syndrome. J. Am. Soc. Nephrol. 14, 2767-2774 (2003).
61. Oliver, J. A., Maarouf, O., Cheema, F. H., Martens, T. P. & Al-Awqati, Q. The renal papilla is a niche for adult kidney stem cells. J. Clin. Invest. 114, 795-804 (2004).
62. Stuart, E. T., Haffner, R., Oren, M. & Gruss, P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 14, 5638-5645 (1995).
63. Hewitt, S. M. et al. Transcriptional activation of the bcl-2 apoptosis suppressor gene by the paired box transcription factor PAX8. Anticancer Res. 17, 3211-3215 (1997).
64. Macchia, P. E. et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nature Genet. 19, 83-86 (1998).
65. Igarashi, T. et al. Aberrant expression of Pax-2 mRNA in renal cell carcinoma tissue and parenchyma of the affected kidney. Int. J. Urol. 8, 60-64 (2001).
66. Daniel, L. et al. Pax-2 expression in adult renal tumors. Hum. Pathol. 32, 282-237 (2001).
67. Schaner, M. E. et al. Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell 14, 4376-4386 (2003).
68. Khoubehi, B. et al. Expression of the developmental and oncogenic PAX2 gene in human prostate cancer. J. Urol. 165, 2115-2120 (2001).
69. Dressler, G. R. & Douglass, E. C. Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc. Natl Acad. Sci. USA 89, 1179-1183 (1992).
70. Davies, J. A., Perera, A. D. & Walker, C. L. Mechanisms of epithelial development and neoplasia in the metanephric kidney. Int. J. Dev. Biol. 43, 473-478 (1999).
71. Lui, W. O. et al. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARγ fusion oncogene. Oncogene 24, 1467-1476 (2005).
72. Scouten, W. T. et al. Cytoplasmic localization of the paired box gene, Pax-8, is found in pediatric thyroid cancer and may be associated with a greater risk of recurrence. Thyroid 14, 1037-1046 (2004).
73. Ferretti, E. et al. Expression, regulation, and function of PAX8 in the human placenta and placental cancer cell lines. Endocrinology 146, 4009-4015 (2005).
74. Lacroix, L. et al. PAX8 and peroxisome proliferator-activated receptor γ 1 gene expression status in benign and malignant thyroid tissues. Eur. J. Endocrinol. 151, 367-374 (2004).
75. Marques, A. R. et al. Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 87, 3947-3952 (2002).
76. Marques, A. R. et al. Underexpression of peroxisome proliferator- activated receptor (PPAR)γ in PAX8-PPARγ-negative thyroid tumours. Br. J. Cancer 91, 732-738 (2004).
77. Dwight, T. et al. Involvement of the PAX8-peroxisome proliferator- activated receptor γ rearrangement in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 88, 4440-4445 (2003).
78. Nikiforova, M. N., Biddinger, P. W., Caudill, C. M., Kroll, T. G. & Nikiforov, Y. E. PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am. J. Surg. Pathol. 26, 1016-1023 (2002).
79. Nikiforova, M. N. et al. RAS point mutations and PAX8-PPAR γ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88, 2318-2326 (2003).
80. Cheung, L et al. Detection of the PAX8-PPARγ fusion oncogene in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 88, 354-357 (2003).
81. Kroll, T. G. et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289, 1357-1360 (2000).
82. Gregory Powell, J. et al. The PAX8-PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene 23, 3634-3641 (2004).
83. McIver, B., Grebe, S. K. & Eberhardt, N. L. The PAX8- PPARγfusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr. Drug Targets Immune Endocr. Metabol. Disord 4, 221-234 (2004).
84. Busslinger, M. Transcriptional control of early B cell development. Annu. Rev. Immunol. 22, 55-79 (2004).
85. Urbanek, P., Wang, Z. Q., Fetka, I., Wagner, E. F. & Busslinger, M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 79, 901-912 (1994).
86. Horowitz, M. C. et al. Pax5-deficient mice exhibit early onset osteopenia with increased osteoclast progenitors. J. Immunol. 173, 6583-6591 (2004).
87. Hirokawa, S., Sato, H., Kato, I. & Kudo, A. EBF-regulating Pax5 transcription is enhanced by STAT5 in the early stage of B cells. Eur. J. Immunol. 33, 1824-1829 (2003).
88. Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest. 109, 1139-1142 (2002).
89. Yu, H. & Jove, R. The STATs of cancer - new molecular targets come of age. Nature Rev. Cancer. 4, 97-105 (2004).
90. Zhang, X., Lin, Z. & Kim, I. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias. J. Korean Med. Sci. 18, 804-808 (2003).
91. Krenacs, L. et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 92, 1308-1316 (1998).
92. Poppe, B. et al. PAX5-IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 44, 218-223 (2005).
93. Ohno, H., Ueda, C. & Akasaka, T. The t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. Leuk. Lymphoma 36, 435-445 (2000).
94. Stuart, E. T., Kioussi, C., Aguzzi, A. & Gruss, P. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin. Cancer Res. 1, 207-214 (1995).
95. Baumann Kubetzko, F. B. et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 25, 1839-1846 (2004).
96. Kozmik, Z., Sure, U., Ruedi, D., Busslinger, M. & Aguzzi, A. Deregulated expression of PAX5 in medulloblastoma. Proc. Natl Acad. Sci. USA 92, 5709-5013 (1995).
97. Maulbecker, C. C. & Gruss, P. The oncogenic potential of Pax genes. EMBO J. 12, 2361-2367 (1993).
98. Miyamoto, T. et al. Expression of dominant negative form of PAX4 in human insulinoma. Biochem. Biophys. Res. Commun. 282, 34-40 (2001).
99. Chi, N. & Epstein, J. A. Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 18, 41-47 (2002).
100. Pichaud, F. & Desplan, C. Pax genes and eye organogenesis. Curr. Opin. Genet. Dev. 12, 430-434 (2002).
101. Simpson, T. I. & Price, D. J. Pax6; a pleiotropic player in development. Bioessays 24, 1041-1051 (2002).
102. Hill, R. E. et al. Mouse small eye results from mutations in a paired-like homeobox-containing gene. Nature 354, 522-525 (1991).
103. Stoykova, A., Fritsch, R., Walther, C. & Gruss, P. Forebrain patterning defects in small eye mutant mice. Development 122, 3453-3465 (1996).
104. Sander, M. et al. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes Dev. 11, 1662-1673 (1997).
105. Philips, G. T. et al. Precocious retinal neurons: Pax6 controls timing of differentiation and determination of cell type. Dev. Biol. 279, 308-321 (2005).
106. Tian, N. M. & Price, D. J. Why cavefish are blind. Bioessays 27, 235-238 (2005). This paper provides an excellent account of how Pax6 regulates the degeneration of eye primordia to produce blind cavefish.
107. Ooto, S. et al. Potential for neural regeneration after neurotoxic injury in the adult mammalian retina. Proc. Natl Acad. Sci. USA 101, 13654-13659 (2004).
108. van Heyningen, V. & Williamson, K. A. PAX6 in sensory development. Hum. Mol. Genet. 11, 1161-1167 (2002).
109. Halder, G., Callaerts, P. & Gehring, W. J. Induction of ectopic eyes by targeted expression of the eyeless gene in Drosophila. Science 267, 1788-1792 (1995).
110. Altmann, C. R., Chow, R. L., Lang, R. A. & Hemmati-Brivanlou, A. Lens induction by Pax-6 in Xenopus laevis. Dev. Biol. 185, 119-123 (1997).
111. Jones, P. A. et al. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc. Natl Acad. Sci. USA 87, 6117-6121 (1990).
112. Liang, G. et al. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 53, 260-268 (1998).
113. Salem, C. E. et al. PAX6 methylation and ectopic expression in human tumor cells. Int. J. Cancer 87, 179-185 (2000).
114. Nguyen, C. et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J. Natl Cancer Inst. 93, 1465-1472 (2001).
115. Ballestar, E. et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 22, 6335-6345 (2003). This paper shows that silencing of PAX6 could contribute to the progression of breast cancer.
116. Rodrigo, I., Hill, R. E., Balling, R., Munsterberg, A. & Imai, K. Pax1 and Pax9 activate Bapx1 to induce chondrogenic differentiation in the sclerotome. Development 130, 473-482 (2003).
117. Peters, H., Neubuser, A., Kratochwil, K. & Balling, R. Pax9-deficient mice lack pharyngeal pouch derivatives and teeth and exhibit craniofacial and limb abnormalities. Genes Dev. 12, 2735-2747 (1998).
118. Klein, M. L., Nieminen, P., Lammi, L., Niebuhr, E. & Kreiborg, S. Novel mutation of the initiation codon of PAX9 causes oligodontia. J. Dent. Res. 84, 43-47 (2005).
119. Lammi, L. et al. A missense mutation in PAX9 in a family with distinct phenotype of oligodontia. Eur. J. Hum. Genet. 11, 866-871 (2003).
120. Das, P. et al. Haploinsufficiency of PAX9 is associated with autosomal dominant hypodontia. Hum. Genet. 110, 371-376 (2002).
121. Stockton, D. W., Das, P., Goldenberg, M., D'Souza, R. N. & Patel, P. I. Mutation of PAX9 is associated with oligodontia. Nature Genet. 24, 18-19 (2000).
122. Peters, H. et al. Pax1 and Pax9 synergistically regulate vertebral column development. Development 126, 5399-5408 (1999).
123. Yoo, B. S. et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the regulation of Pax5 in lipopolysaccharide-activated B cells. Toxicol. Sci. 77, 272-279 (2004).
124. Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
125. Du, J. et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6, 565-576 (2004).
126. Treisman, J., Harris, E. & Desplan, C. The paired box encodes a second DMA-binding domain in the paired homeo domain protein. Genes Dev. 5, 594-604 (1991).
127. Ward, T. A., Nebel, A., Reeve, A. E. & Eccles, M. R. Alternative messenger RNA forms and open reading frames within an additional conserved region of the human PAX-2 gene. Cell Growth Differ. 5, 1015-1021 (1994).
128. Rinkenberger, J. L., Wallin, J. J., Johnson, K. W. & Koshland, M. E. An interleukin-2 signal relieves BSAP (Pax5)-mediated repression of the immunoglobulin J chain gene. Immunity 5, 377-386 (1996).
129. Pearton, D. J., Yang, Y. & Dhouailly, D. Transdifferentiation of corneal epithelium into epidermis occurs by means of a multistep process triggered by dermal developmental signals. Proc. Natl Acad. Sci. USA 102, 3714-3719 (2005).
130. Jonker, L., Kist, R., Aw, A., Wappler, I. & Peters, H. Pax9 is required for filiform papilla development and suppresses skin-specific differentiation of the mammalian tongue epithelium. Mech. Dev. 121, 1313-1322 (2004).